CaroGen Corporation has been awarded a $3 million Phase 2b SBIR grant from the National Institutes of Health (NIH) to advance its lead clinical candidate in infectious diseases, CARG-201, toward human clinical trials for patients chronically infected with hepatitis B virus (HBV).
CARG-201 is being developed by collaborative efforts of CaroGen, Yale University School of Medicine, and Albany Medical College.